Pituitary/growth disorders


Vosoritide may be given to children with achondroplasia aged under 60 months after phase 2 trial findings point to a tolerable adverse event profile and an increase in height Z score compared with placebo.
Exome sequencing and chromosomal microarray analysis are useful tools for the identification of genetic causes underlying short stature, indicate the results of a systematic review and meta-analysis.
Gonadotropin-releasing hormone agonist therapy in children with congenital adrenal hyperplasia does not compromise bone mineral density, US researchers say.
The Guideline Development Group has created a set of UK guidelines to aid clinicians in the diagnosis and treatment of children and young people with adamantinomatous craniopharyngiomas.

In depth

We are delighted to announce the upcoming Springer Healthcare IME Symposium, entitled Insights into MAnaging Growth for Endocrine Nurses (IMAGE). This meeting will take place on the 21–22 March 2024 at the Westminster Hotel and Spa, Nice, France.
This is the 9th IMAGE programme, which focuses on transgender management, bone health, and the genetics and treatment of growth disorders.
Professor Martin Savage discusses the roles of clinical, endocrinological and genetic testing in the diagnosis and care of children with idiopathic short stature.
Why is the growth plate the most important organ for childhood growth: how can it be investigated for clinical diagnosis?
Martin Savage
Programme Director

Sign up for eAlerts

Be the first to hear about new resources and content by signing up to receive our eAlerts.

Please provide your details:

We'd love your feedback!

Please complete this short 4-question survey to help improve the content offered on this website.
How would you rate the following aspects of the website?
How do would you rate the following educational products on the website in 2023?